> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-229/
- Published: 2019-06-23T12:00:00.000Z
- Updated: 2026-09-15T01:34:21.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144409

[**Priority Review Voucher Awarded to AveXis**](https://www.fdaweb.com/priority-review-voucher-awarded-to-avexis/)  
*Federal Register* notice: FDA announces that it issued a priority review voucher to AveXis for gaining approval for its rare pediatric disease product Zolgensma (onasemnogene abeparvovec-xioi). 06/21/2019

[**Panel to Review Gilead sNDA for Descovy**](https://www.fdaweb.com/panel-to-review-gilead-snda-for-descovy/)  
*Federal Register* notice: FDA announces an 8/7 Antimicrobial Drugs Advisory Committee meeting to discuss a Gilead Sciences supplemental NDA for Descovy. 06/21/2019

[**Draft Guide on Opioid Benefit-Risk Assessments**](https://www.fdaweb.com/draft-guide-on-opioid-benefit-risk-assessments/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework.” 06/21/2019

[**Hearing on Standards for Future Opioid Analgesic Approvals**](https://www.fdaweb.com/hearing-on-standards-for-future-opioid-analgesic-approvals/)  
*Federal Register* notice: FDA announces a 9/17 public hearing entitled “Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeutics to Treat Pain and Addiction.” 06/20/2019

[**Info Collection for GRAS Substance Notifications**](https://www.fdaweb.com/info-collection-for-gras-substance-notifications/)  
*Federal Register* notice: FDA submits to OMB an information collection extension for “Substances Generally Recognized as Safe (GRAS): Notification Procedure.” 06/20/2019

[**Pediatric Oncology Subcommittee Meeting Amended**](https://www.fdaweb.com/pediatric-oncology-subcommittee-meeting-amended/)  
*Federal Register* notice: FDA amends a 5/6 Federal Register notice about a 6/20 meeting of the Oncologic Drugs Advisory Committee’s Pediatric Oncology Subcommittee. 06/20/2019

[**Comments Extended for Cannabis Product Info**](https://www.fdaweb.com/comments-extended-for-cannabis-product-info/)  
*Federal Register* notice: FDA extends the comment period until 7/16 that seeks input and scientific data about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis. 06/19/2019

[**Info Collection on OTC Drug Labeling Format**](https://www.fdaweb.com/info-collection-on-otc-drug-labeling-format/)  
*Federal Register* notice: FDA seeks comments on an information collection extension entitled “Format and Content Requirements for Over-the-Counter Drug Product Labeling — 21 CFR Part 201.” 06/19/2019

[**Info Collection Extension for Social/Behavioral Research**](https://www.fdaweb.com/info-collection-extension-for-social-behavioral-research/)  
*Federal Register* notice: FDA seeks comments on an information collection extension for “Data to Support Social and Behavioral Research as Used by the Food and Drug Administration.” 06/18/2019

[**Info Collection Extension on Device Postmarket Surveillance**](https://www.fdaweb.com/info-collection-extension-on-device-postmarket-surveillance/)  
*Federal Register* notice: FDA seeks comments on an information collection extension entitled “FDA Postmarket Surveillance of Medical Devices — 21 CFR Part 822” (OMB Control Number 0910-0449). 06/18/2019